In 802 overweight or obese adults enrolled in the 2-year POUNDS Lost randomized trial, higher baseline plasma erythritol, arabitol/xylitol, and mannitol/sorbitol each independently predicted greater 10-year ASCVD risk scores (β ≈ +1.1–1.3% per 1 SD, p<0.001). Critically, only erythritol reductions at 6 months tracked meaningfully with cardiovascular improvement: each 1 SD fall in plasma erythritol corresponded to a −0.16% reduction in ASCVD risk at 6 months and a −0.26% reduction at 2 years, alongside lower cholesterol in VLDL+LDL particles carrying apolipoprotein C-III — a particularly atherogenic lipid subfraction.
This finding lands at a timely intersection of two fast-moving fields: the metabolic consequences of sugar-alcohol consumption and the search for cardiometabolic biomarkers beyond standard LDL. ApoC-III-enriched remnant particles are increasingly recognized as causal in atherosclerosis, making their reduction especially meaningful. The erythritol signal is notable because erythritol is now widely used as a low-calorie sweetener, yet endogenous production from glucose via the pentose-phosphate pathway may dominate circulating levels — meaning falling erythritol may partly reflect improved glucose metabolism rather than reduced dietary intake.
Limitations are substantial: this is an observational sub-analysis of a randomized trial, not a controlled erythritol-intervention study; causality cannot be established; polyol measurements occurred at only two time points; and the ASCVD endpoint is an estimated, not observed, risk score. Still, the specificity of erythritol over the other polyols, combined with the apoC-III mechanism, makes this incrementally important evidence worth monitoring.